IP Library Granted Patent US 7,766,954
Granted Patent B2
US 7,766,954 · App. 11/333,595 · Granted Aug 3, 2010

Advanced endovascular graft

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,766,954
App. No.
11/333,595
Granted
Aug 3, 2010
Kind
B2
Abstract

This invention is a system for the treatment of body passageways; in particular, vessels with vascular disease. The system includes an endovascular graft with a low-profile delivery configuration and a deployed configuration in which it conforms to the morphology of the vessel or body passageway to be treated as well as various connector members and stents. The graft is made from an inflatable graft body section and may be bifurcated. One or more inflatable cuffs may be disposed at either end of the graft body section. At least one inflatable channel is disposed between and in fluid communication with the inflatable cuffs.

Claims (27)

1. An endovascular graft comprising:

a graft body section having an inflatable cuff and wherein the inflatable cuff contains a three-component inflation medium, wherein the inflation medium comprises the combination of polyethylene glycol diacrylate with pentaerthyritol tetra 3(mercaptopropionate) or a thiolated polyethyleneamine, and a buffer.

2. The endovascular graft of claim 1 wherein the buffer comprises glycylglycine.

3. The endovascular graft of claim 1 wherein the buffer comprises triethanolamine in phosphate-buffered saline.

4. The endovascular graft of claim 1 wherein the polyethylene glycol diacrylate is present in a proportion ranging from about 50 to about 55 weight percent.

5. The endovascular graft of claim 1 wherein the polyethylene glycol diacrylate has a molecular weight ranging from about 350 to about 850.

6. The endovascular graft of claim 1 wherein the pentaerthyritol tetra 3(mercaptopropionate) is present in a proportion ranging from about 22 to about 27 weight percent.

7. The endovascular graft of claim 2 wherein the glycylglycine is present in a proportion ranging from about 22 to about 27 weight percent.

8. The endovascular graft of claim 1 wherein a post-cure elastic modulus of the inflation medium is between about 175 and about 250 pounds per square inch.

9. The endovascular graft of claim 8 wherein the inflation medium exhibits a cure time between about two minutes and about ten minutes.

10. The endovascular graft of claim 1 wherein the inflation medium additionally comprises saline or other inert biocompatible material.

11. The endovascular graft of claim 10 wherein the inflation medium comprises between about 20 and about 50 percent by volume saline.

12. The endovascular graft of claim 1 wherein the graft body section comprises an inflatable channel in fluid communication with the inflatable cuff.

13. The endovascular graft of claim 12 wherein the inflatable cuff is disposed at a proximal portion of the graft body section and further comprising a second inflatable cuff disposed at a distal portion of the graft body section and wherein the second inflatable cuff is in fluid communication with the inflatable channel and inflatable cuff.

14. An endovascular graft comprising:

a graft body section having an inflatable cuff and wherein the inflatable cuff contains an inflation medium that comprises two components, a buffer, and a radiopaque material comprising an iodinated aqueous solution.

15. The endovascular graft of claim 14 wherein the buffer comprises a glycylglycine.

16. The endovascular graft of claim 14 wherein the inflation material becomes less radiopaque over time.

17. The endovascular graft of claim 14 further comprising an insoluble contrast agent.

18. The endovascular graft of claim 17 wherein the insoluble contrast agent comprises barium sulfate.

19. An endovascular graft comprising:

a graft body section having an inflatable cuff and wherein the inflatable cuff contains a three-component inflation medium that cures via a Michael addition process, wherein the inflation medium comprises a polymer having conjugated unsaturated groups, a nucleophile and a buffer.

20. The graft of claim 19 wherein the unsaturated groups are selected from the group consisting of acrylate, acrylamide, quinine, vinylpyridinium and combinations thereof.

21. The graft of claim 19 wherein the polymer is selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(ethylene-co-vinyl alcohol), poly(acrylic acid), poly(ethylene-co-acrylic acid), poly(ethyloxazoline), poly(vinyl pyrrolidone), poly(ethylene-co-vinyl pyrrolidone), poly(maleic acid), poly(ethylene-co-maleic acid), poly(acrylamide), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, and combinations or copolymers thereof.

22. The graft of claim 19 wherein the nucleophile is selected from the group consisting of thiols, amines and combinations thereof.

23. The graft of claim 19 wherein the polymer is a polyethylene glycol diacrylate and the nucleophile is a thiol.

24. The graft of claim 23 wherein the nucleophile is trimethylolpropane tris(3-mercaptopropionate), pentaerythritol tetrakis (3-mercaptopropionate) or combinations thereof.

Assignments (9)
SECURITY INTEREST Recorded Apr 1, 2021
From: TRIVASCULAR, INC.
To: SILICON VALLEY BANK
Reel/Frame 055794/0938 →
SECURITY INTEREST Recorded Oct 2, 2020
From: ENDOLOGIX LLC (F/K/A ENDOLOGIX, INC.); NELLIX, INC.; TRIVASCULAR TECHNOLOGIES, INC.; TRIVASCULAR, INC.; TRIVASCULAR CANADA, LLC
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P.
Reel/Frame 053971/0052 →
CHANGE OF NAME Recorded Oct 2, 2020
From: ENDOLOGIX, INC.
To: ENDOLOGIX LLC
Reel/Frame 053971/0135 →
SECURITY INTEREST Recorded Aug 10, 2018
From: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
To: DEERFIELD ELGX REVOLVER, LLC, AS AGENT
Reel/Frame 046762/0169 →
RELEASE OF SECURITY INTEREST Recorded Jan 12, 2018
From: DEERFIELD ELGX REVOLVER, LLC, AS AGENT
To: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
Reel/Frame 045059/0971 →
SECURITY INTEREST Recorded Apr 3, 2017
From: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
To: DEERFIELD ELGX REVOLVER, LLC, AS AGENT
Reel/Frame 042146/0454 →
SECURITY INTEREST Recorded Apr 3, 2017
From: ENDOLOGIX, INC.; NELLIX, INC.; TRIVASCULAR, INC.
To: DEERFIELD PRIVATE DESIGN FUND IV, L.P., AS AGENT
Reel/Frame 042141/0354 →
RELEASE OF SECURITY INTEREST IN PATENT RIGHTS Recorded Feb 4, 2016
From: CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: TRIVASCULAR, INC.
Reel/Frame 037701/0097 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Oct 12, 2012
From: TRIVASCULAR, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 029117/0323 →